Who We Are
Frazier Life Sciences is a healthcare investment firm focusing on companies developing novel therapeutics. We have two core funds that enable investments across all stages of therapeutics companies:
Our Venture Funds primarily invest in private companies, focusing on company creation (over 30 companies formed since 2005) and Series A & B companies. We form true partnerships with distinctive entrepreneurs to build highly valuable companies and accelerate advancement of new therapeutic options for patients. Our latest Venture Fund is Frazier Life Sciences XI, a $987 million fund that was raised in 2022.
Our Public Funds provide capital to small- and mid-cap public biotech companies in financings, including follow-ons including CMPOs, PIPEs, IPOs, as well as supporting our companies in the open market. We partner with our public portfolio companies much as we do with our private portfolio companies. The Public Funds are investing over $1 billion of committed capital.
Ojjaara (momelotinib) approved in the US as the first and only…
Ojjaara (momelotinib) approved in the US as the first and only treatment…link
Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product…
Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio…link
AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten…
AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering…link
Novartis completes acquisition of Chinook Therapeutics
Novartis completes acquisition of Chinook Therapeuticslink
Our goal is to invest in therapeutics that ultimately benefit patients, and our portfolio has generated over 40 FDA approved therapeutics since 2010. Examples include:
Certain statements about Frazier Life Sciences made by portfolio company executives herein are intended to illustrate the work of Frazier’s team with such portfolio companies. Portfolio company executives were not compensated in connection with their participation, although they generally receive compensation and investment opportunities in connection with their portfolio company roles, and in certain cases are also owners of portfolio company securities, Senior Advisors, and/or investors in Frazier-sponsored vehicles. Such compensation and investments subject participants to potential conflicts of interest in making the statements herein.